using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein.

These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to traditional, chemically synthesized medicines. In Germany HEXAL employs more then 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.